Eli Lilly and Co. (NYSE:LLY) reported on Thursday topline results from its Phase 3 TRIUMPH-1 trial evaluating experimental obesity treatment retatrutide, with patients losing as much as 28.3% of body weight after 80 weeks of treatment.

The study evaluated retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways, in adults with obesity or overweight and at least one weight-related condition, excluding diabetes patients.

Higher Doses Produced Greater Weight Loss

Lilly said patients receiving the 12 mg dose lost an average of 70.3 pounds, or 28.3% of body weight, while those taking the 9 mg dose lost 64.4 pounds, or 25.9%.

Participants on the 4 mg dose lost an average of 47.2 pounds, equivalent to 19% body weight reduction.

The company said all doses met the study's primary and key secondary endpoints.

According to the results, 65.3% of participants taking the 12 mg ...